Patent Classification

Treatment, Inflammation Related Disorders

1. Method of treating or inhibiting inflammation by multi-domain amphipathic helical peptides
    
2. Reagents, methods and systems to suppress pro-inflammatory cytokines
    
3. Combining therapies targeting multiple toll-like receptors
    
4. Milk fractions and milk preparations for treating and/or preventing COX-2 mediated diseases
    
5. Small peptides and methods for treatment of inflammation
    
6. Anti-factor B antibodies
    
7. Method and composition for modulation of systemic inflammatory responses syndrome (SIRS)
    
8. Anti-inflammatory and/or analgesic composition for the intestine comprising branched maltodextrins
    
9. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
    
10. Method for modulating inflammatory responses by altering plasma lipid levels
     
11. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
     
12. Method for treating inflammatory diseases of the digestive tract
     
13. Antibodies to toll-like receptor-2
     
14. Marker for inflammatory conditions
     
15. Enamel matrix protein composition for treatment of systemic inflammatory response syndrome
     
16. Drug design based on the structure of LTA.sub.4 hydrolase
     
17. Antagonists of HMG1 for treating inflammatory conditions
     
18. Antibodies against interleukin-1.beta.
     
19. Humanized Fc.gamma.RIIB-specific antibodies and methods of use thereof
     
20. Non-neutralizing anti-aPC antibodies
     
21. Metalloproteinase-binding proteins
     
22. Method of treating inflammatory disease by inhibition of IL-17 production
     
23. Integrin linked kinase modulation of monocyte activation
     
24. Anti-OX40L antibodies
     
25. Methods of treating inflammatory disease using antibodies which bind GPR-9-6
     
26. Therapeutic compositions for intranasal administration which include KETOROLAC
     
27. NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
     
28. Preparations for the application of anti-inflammatory agents
     
29. Methods of using IL-1 antagonists to treat autoinflammatory disease
     
30. Method of modulating inflammatory response
     
31. Methods of treating inflammation using mammalian CX.sub.3C chemokine antibodies
     
32. Copper lowering treatment of inflammatory and fibrotic diseases
     
33. Recombinant poxvirus
     
34. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
     
35. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
     
36. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
     
37. Matrix protein composition for treating inflammation
     
38. Anti-inflammatory cranberry flavonol extract preparations
     
39. Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
     
40. Highly purified mocarhagin, a cobra venom protease, polynucleotides encoding same and related proteases, and therapeutic uses thereof
     
41. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
     
42. Compositions for alleviating inflammation and oxidative stress in a mammal
     
43. Methods and compositions for modulating immune response and for the treatment of inflammatory disease
     
44. Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
     
45. Antagonists of HMG1 for treating inflammatory conditions
     
46. Nimesulide gel systems for topical use
     
47. Treatment of optic and otic inflammation
     
48. Anti-inflammatory peptides derived from C-reactive protein
     
49. Use of prenylated flavones
     
50. Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease
     
51. Methods of treating joint inflammation with anti-TNF antibodies
     
52. Antagonists of HMG1 for treating inflammatory conditions
     
53. Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
     
54. Method and reagent for testing for multiple organ failure in SIRS by cytochrome C measurement
     
55. Dietary control of arachidonic acid metabolism
     
56. Methods of treating inflammation using antibodies to M-CSF
     
57. TNF receptor death domain ligand proteins and inhibitors of ligand binding
     
58. Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
     
59. Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
     
60. Methods for screening compounds that bind human COE-2
     
61. Method of treating musculoskeletal and connective tissue inflammations
     
62. Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
     
63. Stimulating neutrophil function to treat inflammatory bowel disease
     
64. Method for prevention and/or treatment of infections and inflammatory conditions using a combination of lactic acid bacteria
     
65. Probiotic compositions for the treatment of inflammatory bowel disease
     
66. Treatment of inflammatory disease
     
67. Method for screening compounds inhibiting signal transduction through inflammatory cytokines
     
68. Synergistic proteoglycan compositions for inflammatory conditions
     
69. Oral composition and method for the treatment of inflammatory cutaneous disorders
     
70. Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
     
71. Method for the treatment of inflammatory disorders
     
72. Biomarkers for oxidative stress
     
73. Method for binding basophils and mast cells
     
74. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
     
75. Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
     
76. Anti-inflammatory peptides derived from IL-2 and analogues thereof
     
77. Method for the treatment of inflammation
     
78. Method of using IL-11 for treating mucositis
     
79. Modulation of systemic memory T cell trafficking
     
80. Administration of resveratrol to treat inflammatory respiratory disorders
     
81. Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions
     
82. Method for screening compounds for anti-inflammatory activity
     
83. PYK2 and inflammation
     
84. Copper lowering treatment of inflammatory and fibrotic diseases
     
85. Plaster containing felbinac
     
86. Composition and method for treating the effects of diseases and maladies
     
87. Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
     
88. Compositions and methods for the treatment or prevention of inflammation
     
89. Porous COX-2 inhibitor matrices and methods of manufacture thereof
     
90. Fragments of CR1 and their use
     
91. Topical application of cetirizine and loratadine
     
92. Anti-inflammatory pharmaceutical formulations
     
93. Mesalazine controlled release oral pharmaceutical compositions
     
94. Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
     
95. Composition and method for treatment of conditions having an inflammatory component
     
96. Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation
     
97. Human secretory type phospholipase a2
     
98. LIF for use in modulating inflammation and pain
     
99. Therapy for cellular accumulation in chronic inflammatory diseases
     
100. Modulation of .gamma..delta. T cells to regulate airway hyperresponsiveness
      
101. Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
      
102. Composition and method for treating inflammatory diseases
      
103. Delivery on nonsteroidal antiinflammatory drugs through an inhalation route
      
104. Controlled release formulation for treating COPD
      
105. Pharmaceutical composition capable of regulating the expression of adhesion molecules
      
106. Conjugate for treating inflammatory infectious and/or skin diseases
      
107. Marker for inflammatory conditions
      
108. Transdermal delivery of an anti-inflammatory composition
      
109. Labeled humanized anti-CD18 antibodies and fragments and kits comprising same
      
110. Use of melagatran
      
111. Methods for treatment of inflammatory diseases
      
112. Method of treating systemic inflammatory response syndrome
      
113. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
      
114. Inhibitor of the inflammatory response induced by TNF.alpha. and IL-1
      
115. Method for inhibiting inflammatory responses
      
116. Proteoglycan compositions for treating prostate and bladder inflammatory conditions
      
117. Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
      
118. Proteoglycan compositions for treatment of cardiovascular inflammatory diseases
      
119. Rantes mutants and therapeutic applications thereof
      
120. Models of chronic and acute inflammatory diseases
      
121. NK-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
      
122. Preventives/remedies for inflammatory intestinal disease
      
123. Methods for treating cell death diseases and inflammation
      
124. Methods for treatment of inflammatory diseases
      
125. Intercellular adhesion molecule--2 and its binding ligands
      
126. Method and composition for treating mammalian disease caused by inflammatory response
      
127. High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
      
128. Transdermal patch for nonsteroidal antiinflammatory drug(s)
      
129. Antagonists of HMG1 for treating inflammatory conditions
      
130. Methods of treating chronic inflammatory diseases using carbonyl trapping agents
      
131. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
      
132. Anti-Inflammatory herbal composition and method of use
     
     
133. Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 .alpha. subunit
     
     
134. Method for treating inflammatory diseases by administering a thrombin inhibitor
     
     
135. C5-specific antibodies for the treatment of inflammatory diseases
     
     
136. Cytokine suppressive anti-inflammatory drug binding protein
     
     
137. Lipid extract having anti-inflammatory activity
     
     
138. Anti-inflammatory compositions comprising peptide derivatives of .alpha.-MSH/algal extracts
      
     
139. Therapeutic compositions for intranasal administration which include KETOROLAC.RTM.
      
     
140. Anti-CCR1 antibodies and methods of use therefor
      
     
141. Nimesulide topical formulations in the form of liquid crystals
      
     
142. Method of preparing an extract potent in anti-inflammation and anti-platelet aggregation from Zingiber officinale and pharmaceutical compositions containing said extract
      
     
143. Method of using IL-11 for treating gingivitis
      
     
144. Stable aspirin-containing preparations for external use
      
     
145. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
      
     
146. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
      
     
147. Method for treatment of inflammatory disease
      
     
148. Modulation of systemic memory T cell trafficking
      
     
149. Anti-flammatory carbohydrate binding-peptides
      
     
150. Compositions and methods for treating mast-cell mediated conditions

Treatment, Influenza/Avian Flu

1. Vaccines against multiple subtypes of influenza virus
    
2. Antiviral peptides against influenza virus
    
3. Functional influenza virus like particles (VLPs)
    
4. Real-time detection of influenza virus
    
5. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
    
6. Vero cell-based influenza virus strains and vaccines
    
7. Method for producing the flu virus
    
8. Replikin peptides in rapid replication of glioma cells and in influenza epidemics
    
9. Protein D--an IGD binding protein of Haemophilus influenzae
    
10. Development of influenza A antivirals
     
11. Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
     
12. Influenza vaccine
     
13. Multi plasmid system for the production of influenza virus
     
14. Method of inhibiting influenza infection with antiviral peptides
     
15. Vaccine for nontypeable Haemophilus influenzae infection
     
16. Proteosome influenza vaccine
     
17. Cold-adapted influenza virus
     
18. Method of treating influenza with geranyl-geranyl acetone
     
19. Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
     
20. Influenza vaccine composition
     
21. Potent inhibition of influenza virus by specifically designed short interfering RNA
     
22. Dietary supplement composition for ameliorating inflammatory changes in influenza process
     
23. Peptide-based vaccine for influenza
     
24. Inactivated influenza virus vaccine for nasal or oral application
     
25. Method for generating influenza viruses and vaccines
     
26. Process for producing viral RNA polymerase
     
27. Avian pneumovirus vaccine
     
28. Antigenic class of avian reoviruses
     
29. Temperature-sensitive and cold-adapted human parainfluenza virus type 2 (HPIV-2) and vaccines based on such virus
     
30. Inactivated influenza virus vaccine for nasal or oral application
     
31. Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation
     
32. Proteosome influenza vaccine
     
33. Peptide-based vaccine for influenza
     
34. Throat lozenges for the treatment of Hemosphilus influenza
     
35. Cold-adapted equine influenza viruses
     
36. Inactivated influenza virus vaccine for nasal or oral application
     
37. Influenza sensor
     
38. Influenza vaccine
     
39. Recombinant trytophan mutants of influenza
     
40. Animal cells and processes for the replication of influenza viruses
     
41. Immunogenic conjugates comprising a Group B meningococcal porin and an H influenzae polysaccharide
     
42. Influenza virus vaccine composition
    
    
43. Method of allophycocyanin inhibition of enterovirus and influenza virus reproduction resulting in cytopathic effect
    
    
44. Influenza virus replicated in mammalian cell culture and vaccine production
    
    
45. Method of specifying vaccine components for viral quasispecies
     
    
46. Recombinant tryptophan mutants of influenza

Treatment, Interferon/Interleukin Related Treatments

1. Humanized antibodies against human interferon-alpha
    
2. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
    
3. Methods of using interleukin-2 mutants with reduced toxicity
    
4. IL-17 receptor like molecules and uses thereof
    
5. Anti-interferon alpha monoclonal antibodies and methods for use
    
6. Use of interleukin-18 inhibitors to inhibit tumor metastasis
    
7. Anti-interferon alpha antibodies
    
8. Cysteine variants of alpha interferon-2
    
9. Implantable device for continuous delivery of interferon
    
10. Monoclonal antibodies against interleukin-22
     
11. Co-administration of cG250 and IL-2 or IFN-.alpha. for treating cancer such as renal cell carcinomas
     
12. Modified interferon beta with reduced immunogenicity
     
13. Antibody molecules having specificity for human IL-1.beta.
     
14. Deamidated interferon-.beta.
     
15. Antibodies against interleukin-1.beta.
     
16. Full-length interferon gamma polypeptide variants
     
17. Human antibodies that bind human IL-12
     
18. Interferon-like protein ZCYTO21
     
19. Polymer conjugates of interferon beta-1A and uses
     
20. Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
     
21. Methods of treatment with interferon and albumin fusion protein
     
22. Method of treating IL-10 deficiency
     
23. Method for treating disorders and diseases treatable with human fibroblast interferon
     
24. Glycosylated interferon alpha obtained from a transgenic chicken
     
25. Human anti-IFN-.gamma. neutralizing antibodies as selective IFN-.gamma. pathway inhibitors
     
26. Glycosylated human interferon alpha isoform
     
27. Interferon alpha responsive protein
     
28. Interferon-like protein Zcyto21
     
29. Interferon gamma conjugates
     
30. Use of novel agents inducing cell death in synergy with interferons
     
31. Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
     
32. Anti-interferon-.alpha. antibodies
     
33. Method of treatment using interferon-tau
     
34. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
     
35. Interferon and albumin fusion protein
     
36. Polymer conjugates of interferon beta-1a and uses
     
37. Methods related to immunostimulatory nucleic acid-induced interferon
     
38. Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
     
39. IFN-.beta. liquid formulations
     
40. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
     
41. Ribavirin-pegylated interferon alfa induction HCV combination therapy
     
42. Interferon-beta fusion proteins and uses
     
43. Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R)
     
44. Interferon-beta use in the treatment of ewing's family of tumors
     
45. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
     
46. Carrier for gene detection and its use for detecting validity of interferon therapy
     
47. Polyethylene glycol modified interferon therapy
     
48. Recombiniant gamma interferons having enhanced stability and methods therefor
     
49. Methods and compositions for the dry powder formulation of interferons
     
50. Methods of treating diseased cells
     
51. Keratinocyte derived interferon
     
52. Controlled release of metal cation-stabilized interferon
    
    
53. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
    
    
54. Type I interferons
     
    
55. Interferon-gamma (IFN-.gamma.) inducing factor (IGIF, IL-18) and peptide fragment thereof
     
    
56. Low-toxicity human interferon-alpha analogs

Treatment, Intestinal Lavage

1. Use of 5HT3 antagonists for promoting intestinal lavage

Treatment, Intractable Conditions

1. Dextromethorphan and an oxidase inhibitor for treating intractable conditions

Treatment, In Vitro Fertilization/Fertility Related Disorders

1. In vitro fertilisation
    
2. Methods for in vitro fertilization
    
3. Ovary-specific genes and proteins
    
4. Determination of sperm concentration and viability for artificial insemination
    
5. Antigens for immunocontraception
    
6. Molecule involved in binding of sperm to egg surfaces and procedures for use of this molecule to enhance or decrease potential fertility
    
7. Methods for altering fertility
    
8. Fertility kit
    
9. Methods for in vitro fertilization
    
10. PH sensitive potassium channel in spermatocytes
     
11. Method for determining the fertility of mammals, especially humans
     
12. Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos
     
13. Antigenic peptides reacting with anti-ovary antibodies
     
14. Methods and compositions to improve germ cell and embryo survival and function
     
15. Purified new epididymal forward motility protein and a process for isolation of the said epididymal forward motility protein useful as a fertility promoter/blocker
     
    
16. Treatment of Infertility
     
    
17. Increased fertility and improved fetal development drug
     
    
18. Human SCF, a splice variant thereof, its pharmaceutical use

Treatment, Iron, Deficiency/Overload

1. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
    
2. Porphyrins and metalloporphyrins for inhibiting heme iron uptake
    
3. Iron chelator delivery system
    
4. Mutations associated with iron disorders
    
5. Composition comprising micro-encapsulated iron
    
6. Method of treating iron overload with acetaminophen
    
7. Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases

Treatment, Irritable/Inflammatory Bowel Syndrome

1. Treatment of inflammatory bowel diseases with anti-IP-10 antibodies
    
2. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
    
3. Saccharide compositions and method of use
    
4. Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome
    
5. Methods of enhancing functioning of the large intestine
    
6. Stimulating neutrophil function to treat inflammatory bowel disease
    
7. Agent for treating inflammatory bowel diseases
    
8. Method for treatment of constipation-predominant irritable bowel syndrome
    
9. Methods of suppressing or treating an inflammatory bowel disease by administering an antibody or portion thereof that binds to AILIM
    
10. Treatment of inflammatory bowel disease with IFN-.gamma. inhibitors
     
11. Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
     
12. Treatment of inflammatory bowel disease
     
13. Pharmaceutical composition for the treatment of inflammatory bowel disease
     
14. Agent for treatment of inflammatory bowel disease
     
15. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
     
16. Method for treating inflammatory bowel diseases
     
17. Methods of enhancing functioning of the large intestine
     
18. Treatment for inflammatory bowel disease with .alpha.4-specific antibodies
     
19. Method of treating irritable bowel syndrome
     
20. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
     
21. Treatment of symptoms associated with irritable bowel syndrome
     
22. Probiotic compositions for the treatment of inflammatory bowel disease
     
23. Preparation for regulating lower bowel function
     
24. Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
     
25. Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
     
26. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
     
27. Composition for treatment of constipation and irritable bowel syndrome
     
28. Herbal formulation which acts as an intestinal bowel soother
     
29. Methods for treating irritable bowel syndrome
     
30. Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
    
    
31. Intestinal hydrogen removal using hydrogen-metabolizing microbes

Treatment, Ischemic Related Disorders

1. Use of HMGB1 for protection against ischemia reperfusion injury
    
2. Use of placental growth factor for treating ischemic muscle disease
    
3. Method for mitigating injury to a kidney resulting from an ischemic event
    
4. Identification of a gene expression profile that differentiates ischemic and nonischemic cardiomyopathy
    
5. Method to induce neovascular formation and tissue regeneration
    
6. Use of xenon with hypothermia for treating neonatal asphyxia
    
7. Method and composition for resuscitation
    
8. Compositions and methods for treating peripheral vascular disease
    
9. Method of improving ischemic muscle function by administering placental growth factor
    
10. Methods for evaluating stroke or cardiac ischemia by nucleic acid detection
     
11. Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
     
12. Seventeen amino acid peptide (Peptide P) for treating ischemia and reperfusion injury
     
13. Targeting pharmaceutical agents to injured tissues
     
14. Method for extracting a compound from a ginseng spp. plant, ginseng or pseudo-ginseng
     
15. Method of treating ischemic disease by intramuscular administration of Hepatocyte growth factor
     
16. Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
     
17. CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
     
18. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
     
19. In vitro ischemia model
     
20. Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
     
21. Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
     
22. Method of diagnosing ischemic stroke via UCP-2 detection
     
23. Polydithicarbamate-containing non-targeting marcomolecules and the use thereof for therapeutic and diagnostic applications
     
24. Methods of inhibiting smooth muscle cell proliferation and preventing restenosis with a vector expressing RB2/p130
     
25. Stabilization of cardiac troponin I subunits and complexes
     
26. Method for reducing coronary artery reactivity
     
27. Treatment of ischemic brain injury
     
28. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
     
29. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
     
30. Nicotine in therapeutic angiogenesis and vasculogenesis
     
31. Histochrome and its therapeutic use in acute myocardial infarction and ischemic heart disease
    
    
32. Method for enhancing functional recovery following central nervous system ischemia or trauma
    
    
33. Method for selecting compounds for treating ischemia-related cellular damage
    
    
34. Methods for treating an ischemic disorder and improving stroke outcome
     
    
35. Use of progestins to treat ischemic event

Treatment, Joint/Cartilage Related Disorders

1. Method for repairing a defect in an intervertebral disc
    
2. Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
    
3. Drug delivery to a joint
    
4. Use of neurotoxic substances for the production of a means for the treatment of joint pain and method for application of said means
    
5. Use of neuropeptides for traumatic cartilage injury
    
6. Methods and compositions for repair of cartilage using an in vivo bioreactor
    
7. Compositions for regeneration and repair of cartilage lesions
    
8. Material for treating mammalian joint maladies by biological fluid transplantation
    
9. Methods and compositions for treating intervertebral disc degeneration
    
10. Non-invasive joint evaluation
     
11. Composition and method for treatment of joint damage
     
12. Platelet-derived growth factor compositions and methods of use thereof
     
13. Transdiscal administration of high affinity anti-MMP inhibitors
     
14. Compounds with improved cartilage-inducing and/or bone-inducing activity
     
15. Gene therapy using TGF-.beta.
     
16. Methods and compositions for healing and repair of articular cartilage
     
17. Drugs against articular failure
     
18. Use of botuline toxin to obtain a product to be used in articular pathologies, particularly coxarthrosis, epicondylitis and rotator muscle cap pathology
     
19. Methods of treating joint inflammation with anti-TNF antibodies
     
20. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
     
21. Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
     
22. Therapeutic method
     
23. Osteoarthritis cartilage regeneration
     
24. Gene delivery vectors with cell type specificity for primary human chondrocytes
     
25. Gene therapy using TGF-.beta
     
26. Composition and method for treatment of conditions having an inflammatory component
     
27. Treatment for reactive arthritis or bursitis
     
28. Drugs for prevention and treatment of diseases caused by abnormalities in cartilage tissues
     
29. Therapeutic agent for cartilaginous diseases
     
30. Composition and method for treating inflammatory diseases
     
31. Methods and compositions for healing and repair of articular cartilage
     
32. Product and method for treating joint disorders in vertebrates
     
33. Injectable hyaluronic acid derivative with pharmaceuticals/cells
     
34. Assay of YKL-40 as a marker for cancer
     
35. Product and method for treating joint disorders in vertebrates